EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis

Paulos Gebrehiwet, Saurabh Aggarwal, Ozlem Topaloglu, Adriano Chiò iD

Expert Review of Pharmacoeconomics & Outcomes Research · 2024

DOI: 10.1080/14737167.2024.2306819 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Paulos Gebrehiwet und 3 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics and Outcomes Research, Cytokinetics, Incorporated, South San Francisco, CA, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cytokinetics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study assessed the feasibility of using the Milano-Torino staging (MiToS) system for conducting economic evaluation to measure health outcomes in amyotrophic lateral sclerosis (ALS). METHODS: A Markov model was developed using the MiToS system and evaluated with a hypothetical treatment versus standard of care. Health utilities and transition probabilities were derived from the literature. Four-time horizons (1, 5, 10, and 20 years) were examined. Treatment effects of 20-35% relative risk reduction (RRR) of progressing to the next MiToS stage were assessed. Three patient distribution scenarios were tested: (1) all patients began in stage 0; (2) patient distribution based on real-world TONiC study; (3) distribution based on the PRO-ACT database. Health outcomes (quality-adjusted life-years [QALYs], life-years [LYs]) were reported with a 3% discount rate. RESULTS: A time horizon of 10 years fully captured treatment benefits: incremental QALYs were 0.28-0.60, 0.21-0.45, and 0.26-0.55 for scenarios 1-3, respectively; incremental LYs were 0.56-1.17, 0.46-0.97, and 0.53-1.11, respectively. CONCLUSION: MiToS-based staging can be used for conducting economic analyses in ALS. Estimated incremental QALY and LY gains were meaningful within the context of ALS, for hypothetical treatments with RRR of 20-35%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisHumansCost-Benefit AnalysisFeasibility StudiesMitochondria Associated MembranesDisease ProgressionQuality-Adjusted Life Years

Stichwörter der Autor:innen

Amyotrophic lateral sclerosisMarkov modelMilano-Torino stagingeconomic evaluationhealth outcomes

Autor:innen und Institutionen

  • Health Economics and Outcomes Research, Cytokinetics, Incorporated, South San Francisco, CA, USA.
  • Novel Health Strategies, Chevy Chase, MD, USA.
  • 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.

ORCID-Profile: Adriano Chiò

Förderung

  • Cytokinetics

Zitieren

APA

Gebrehiwet, P., Aggarwal, S., Topaloglu, O., & Chiò, A. (2024). Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2306819

Vancouver

Gebrehiwet P, Aggarwal S, Topaloglu O, Chiò A. Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2024.2306819

BibTeX
@article{Gebrehiwet2024,
  author = {Gebrehiwet, Paulos and Aggarwal, Saurabh and Topaloglu, Ozlem and Chiò, Adriano},
  title = {Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2024},
  doi = {10.1080/14737167.2024.2306819}
}
Kostenlos starten →